182
Participants
Start Date
February 2, 2017
Primary Completion Date
November 23, 2021
Study Completion Date
November 23, 2021
Nivolumab
Specified Dose on Specified Days
Ipilimumab
Specified Dose on Specified Days
Relatlimab
Specified Dose on Specified Days
BMS-986205
Specified Dose on Specified Days
BMS-813160
Specified Dose on Specified Days
Local Institution - 0032, Westmead
Monash Medical Centre Clayton, Bentleigh
Local Institution - 0044, Linz
Local Institution - 0005, New York
Roswell Park Cancer Institute, Buffalo
Local Institution - 0002, Allentown
Local Institution - 0010, Milan
Local Institution - 0007, Baltimore
Local Institution - 0024, Charlottesville
Local Institution - 0043, Charlotte
Hollings Cancer Center, Charleston
Local Institution - 0031, Augusta
Local Institution - 0025, Nashville
Local Institution - 0014, Columbus
Local Institution - 0011, Detroit
Local Institution, Ramat Gan
Local Institution - 0006, Chicago
Local Institution - 0008, St Louis
Local Institution - 0012, Napoli
Oregon Health & Science University, Portland
University of Washington - Seattle Cancer Care Alliance, Seattle
Local Institution, Haifa
Local Institution - 0037, New Haven
Local Institution, Tampa
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Ut Southwestern Medical Center, Dallas
Local Institution - 0038, Hamilton
Local Institution - 0029, Oshawa
Local Institution - 0035, Toronto
Local Institution - 0034, Montreal
Local Institution - 0030, Québec
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY